Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
2024-04-03
ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage Antibody-Drug Conjugate ......
2024-02-14
ProfoundBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of PRO1107, a Protein Tyrosine Kinase 7 (PTK7)-Targeted Anti......
2024-02-05
ProfoundBio Announces Rinatabart Sesutecan FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
2024-01-05
ProfoundBio to Participate in upcoming RBC Capital Markets and JP Morgan Healthcare Conferences
2023-12-05
ProfoundBio Presents Promising Data on ADC Programs, Including Early Clinical Results of Rinatabart Sesutecan in Ovarian and Endom......
2023-11-03
ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment
2023-11-02
ProfoundBio to Participate in the Wells Fargo 2023 Virtual Private Biotech Symposium and Piper Sandler 35th Annual Healthcare Conf......
2023-10-24
